FBRX Forte Biosciences (FBRX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001419041
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
63
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · no price filed
Forte Biosciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Forte Biosciences, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Nov 21, 2024.
- The trade is 23.3% of the 41,520 shares held after it.
- No other insider bought within 30 days.
- 63 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Riley Antony A bought about $254.9K of FBRX on Dec 30, 2025, the largest insider purchase at the company on our record; 63 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 7, 2021.
- The trade is 73.2% of the 30,776 shares held after it.
- No other insider bought within 30 days.
- 63 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Riley Antony A bought about $125.0K of FBRX on Nov 21, 2024, the largest insider purchase at the company on our record; 63 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (12 buys, 1 sale), the last on Dec 14, 2023.
- +12.2% median (+17.2% mean) 90-day return after 10 previous buys.
- The trade is 0.5% of the 1,823,236 shares held after it.
- No other insider bought within 30 days.
- 63 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Wagner Paul A. bought about $7.5K of FBRX on Dec 18, 2023; 63 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (11 buys, 1 sale), the last on Dec 13, 2023.
- +16.2% median (+19.8% mean) 90-day return after 9 previous buys.
- The trade is 0.6% of the 1,813,236 shares held after it.
- No other insider bought within 30 days.
- 63 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Wagner Paul A. bought about $7.2K of FBRX on Dec 14, 2023; 63 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (10 buys, 1 sale), the last on Dec 12, 2023.
- +21.1% median (+22.7% mean) 90-day return after 8 previous buys.
- The trade is 0.6% of the 1,803,236 shares held after it.
- No other insider bought within 30 days.
- 63 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Wagner Paul A. bought about $7.4K of FBRX on Dec 13, 2023; 63 funds added in the latest 13F quarter.18 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
63 funds bought in last quarter
more than 52% of Pharma & Biotech
Revenue
-99.8% year over year
below 92% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
no short interest reported
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch FBRX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+538.9%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns FBRX: institutional holders (13F)
13F holdings, latest reported quarter
2,110,516 sh
$44.8M
1,577,705 sh
$33.5M
1,439,697 sh
$30.6M
1,373,060 sh
$29.2M
1,222,862 sh
$26.0M
Congress trades in FBRX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
FBRX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
FBRX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALGER SMALL CAP GROWTH FUND
$9.8M position · as of 2026-07-31
4.8%
ALGER SMALL CAP GROWTH INSTITUTIONAL FUND
$3.6M position · as of 2026-07-31
4.4%
Lord Abbett Micro-Cap Growth Fund
$5.6M position · as of 2026-07-31
2.6%
ALGER SMALL CAP FOCUS FUND
$21.4M position · as of 2026-07-31
2.5%
Federated Hermes Kaufmann Small Cap Fund
$63.7M position · as of 2026-07-31
2.2%
Federated Hermes Kaufmann Fund
$95.9M position · as of 2026-07-31
1.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 4 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 1
3 active
1
Phase 2
1 active
What changed recently
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Viti
2026-10-27 · Recruiting → Active Not Recruiting
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Dr. Paul Wagner
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$7.4M
$17.8M
$2.7M
+9%
n/a
2024
$1.7M
$1.9M
$543.6K
-9%
n/a
2023
$1.5M
$1.4M
$648.3K
-18%
n/a
2022
$1.2M
$1.0M
$590.1K
-53%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 63 funds added last quarter. Each figure is a federal filing, dated the day it went public.
FBRX financials
Revenue growth
-99.8%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$36.0K
four quarters, 2019-01-01 to 2019-12-31
Revenue, TTM FBRX
| FY Dec 2025 | $36.0K |
| FY Dec 2024 | $36.0K |
| FY Dec 2023 | $36.0K |
| FY Dec 2022 | $36.0K |
| FY Dec 2021 | $36.0K |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM FBRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$72.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM FBRX
| FY Dec 2025 | -$51.0M |
| FY Dec 2024 | -$30.8M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -$8.3M |
| FY Dec 2021 | -$16.8M |
| Jun 2026 | -$22.7M |
| Mar 2026 | -$18.8M |
| Dec 2025 | -$16.5M |
| Sep 2025 | -$14.1M |
| Jun 2025 | -$10.1M |
| Mar 2025 | -$10.4M |
| Dec 2024 | -$10.0M |
| Sep 2024 | -$8.1M |
At each fiscal year end
Single quarter
Debt to equity
0.12x
long-term debt only, 2019-06-30 (85 months older than the period end); equity 2026-06-30
Debt to equity FBRX
| FY Dec 2025 | 0.36x |
| FY Dec 2024 | 0.42x |
| FY Dec 2023 | 0.63x |
| FY Dec 2022 | 0.57x |
| FY Dec 2021 | 0.53x |
| Jun 2026 | 0.12x |
| Mar 2026 | 0.52x |
| Dec 2025 | 0.36x |
| Sep 2025 | 0.26x |
| Jun 2025 | 0.22x |
| Mar 2025 | 0.57x |
| Dec 2024 | 0.42x |
| Sep 2024 | 2.36x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-3.26x
TTM operating cash flow over long-term debt only, 2019-06-30 (85 months older than the period end)
Cash flow to debt FBRX
| FY Dec 2025 | -2.30x |
| FY Dec 2024 | -1.39x |
| FY Dec 2023 | -1.30x |
| FY Dec 2022 | -0.37x |
| FY Dec 2021 | -0.76x |
| Jun 2026 | -3.26x |
| Mar 2026 | -2.69x |
| Dec 2025 | -2.30x |
| Sep 2025 | -2.01x |
| Jun 2025 | -1.75x |
| Mar 2025 | -1.56x |
| Dec 2024 | -1.39x |
| Sep 2024 | -1.35x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-62.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity FBRX
| FY Dec 2025 | -122.3% |
| FY Dec 2024 | -80.8% |
| FY Dec 2023 | -84.9% |
| FY Dec 2022 | -34.5% |
| FY Dec 2021 | -43.2% |
| Jun 2026 | -62.3% |
| Mar 2026 | -188.4% |
| Dec 2025 | -122.3% |
| Sep 2025 | -110.7% |
| Jun 2025 | -73.5% |
| Mar 2025 | -130.3% |
| Dec 2024 | -80.8% |
| Sep 2024 | -137.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-56.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets FBRX
| FY Dec 2025 | -96.1% |
| FY Dec 2024 | -70.6% |
| FY Dec 2023 | -77.7% |
| FY Dec 2022 | -32.5% |
| FY Dec 2021 | -41.5% |
| Jun 2026 | -56.1% |
| Mar 2026 | -132.3% |
| Dec 2025 | -96.1% |
| Sep 2025 | -90.0% |
| Jun 2025 | -63.4% |
| Mar 2025 | -110.0% |
| Dec 2024 | -70.6% |
| Sep 2024 | -103.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital FBRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-63.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed FBRX
| FY Dec 2025 | -123.4% |
| FY Dec 2024 | -83.4% |
| FY Dec 2023 | -87.6% |
| FY Dec 2022 | -34.6% |
| FY Dec 2021 | -42.7% |
| Jun 2026 | -63.4% |
| Mar 2026 | -187.7% |
| Dec 2025 | -123.4% |
| Sep 2025 | -114.3% |
| Jun 2025 | -75.6% |
| Mar 2025 | -133.9% |
| Dec 2024 | -83.4% |
| Sep 2024 | -143.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing FBRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.6B
market value at close 2026-08-28 on 2026-08-07 shares, plus long-term debt only, 2019-06-30 (85 months older than the period end), minus cash 2026-06-30
Enterprise value FBRX
| FY Dec 2025 | $286.7M |
| FY Dec 2024 | $33.0M |
| FY Dec 2023 | $731.6M |
| FY Dec 2022 | $506.0M |
| FY Dec 2021 | $769.4M |
| Jun 2026 | $267.5M |
| Mar 2026 | $323.5M |
| Dec 2025 | $286.7M |
| Sep 2025 | $115.2M |
| Jun 2025 | $1.0M |
| Mar 2025 | $27.3M |
| Dec 2024 | $33.0M |
| Sep 2024 | $209.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-4.4%
TTM free cash flow over market value at close 2026-08-28
FCF yield FBRX
| FY Dec 2025 | -14.9% |
| FY Dec 2024 | -92.7% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -1.6% |
| FY Dec 2021 | -2.1% |
| Jun 2026 | -24.4% |
| Mar 2026 | -16.5% |
| Dec 2025 | -14.9% |
| Sep 2025 | -23.9% |
| Jun 2025 | -45.4% |
| Mar 2025 | -67.6% |
| Dec 2024 | -92.7% |
| Sep 2024 | -14.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing FBRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-08-28. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$70.7M | -$36.6M | -$32.5M | -$13.9M |
| Net income | -$69.4M | -$35.5M | -$31.5M | -$13.9M |
| EPS (diluted) | -4.71 | -12.17 | -24.92 | -0.80 |
| Operating cash flow | -$50.9M | -$30.7M | -$28.7M | -$8.2M |
| Cash | $77.0M | $22.2M | $37.1M | $41.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
FBRX Stock Sonar score 5/7 axes
Find similar shapesCompareFBRX ranks highest on risk and compliance (71st percentile) and institutional and government (52nd), and lowest on growth (8th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
